Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Keating

Showing results (21-30 of 341) with videos related to

Pageof 35
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2016
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower dosesPrithviraj Bose, Varsha V Gandhi, Michael J Keating
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Retrospect of hematological malignancies 2012Emil J Freireich, Hagop Kantarjian, Michael J Keating
Blood|August 16, 2014
Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLLLisa S Chen, Michael J Keating, Varsha Gandhi
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The proceedings of the initial meeting of the Society of Hematologic Oncology 2013Emil J Freireich, Hagop Kantarjian, Michael J Keating
Clinical Lymphoma & Myeloma|September 26, 2009
Leukemia research, 2008Emil J Freireich, Hagop Kantarjian, Michael J Keating
Expert Review of Anticancer Therapy|February 29, 2012
Predicting survival in chronic lymphocytic leukemiaAli Bazargan, Constantine S Tam, Michael J Keating
Expert Opinion on Pharmacotherapy|April 28, 2017
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemiaAbdallah Abou Zahr, Prithviraj Bose, Michael J Keating
Clinical Advances in Hematology & Oncology : H&O|October 6, 2005
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignanciesMichael J Keating, Kanti R Rai, William G Wierda
Nature Reviews. Drug Discovery|May 31, 2008
BendamustineMichael J Keating, Christian Bach, Uma Yasothan, et al.
Nature Reviews. Drug Discovery|February 2, 2010
OfatumumabMichael J Keating, Argyris Dritselis, Uma Yasothan, et al.
Pageof 35

Showing results (21-30 of 341) with videos related to

Sort By:
Pageof 35
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2016
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower dosesPrithviraj Bose, Varsha V Gandhi, Michael J Keating
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Retrospect of hematological malignancies 2012Emil J Freireich, Hagop Kantarjian, Michael J Keating
Blood|August 16, 2014
Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLLLisa S Chen, Michael J Keating, Varsha Gandhi
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The proceedings of the initial meeting of the Society of Hematologic Oncology 2013Emil J Freireich, Hagop Kantarjian, Michael J Keating
Clinical Lymphoma & Myeloma|September 26, 2009
Leukemia research, 2008Emil J Freireich, Hagop Kantarjian, Michael J Keating
Expert Review of Anticancer Therapy|February 29, 2012
Predicting survival in chronic lymphocytic leukemiaAli Bazargan, Constantine S Tam, Michael J Keating
Expert Opinion on Pharmacotherapy|April 28, 2017
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemiaAbdallah Abou Zahr, Prithviraj Bose, Michael J Keating
Clinical Advances in Hematology & Oncology : H&O|October 6, 2005
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignanciesMichael J Keating, Kanti R Rai, William G Wierda
Nature Reviews. Drug Discovery|May 31, 2008
BendamustineMichael J Keating, Christian Bach, Uma Yasothan, et al.
Nature Reviews. Drug Discovery|February 2, 2010
OfatumumabMichael J Keating, Argyris Dritselis, Uma Yasothan, et al.
Pageof 35